<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118986</url>
  </required_header>
  <id_info>
    <org_study_id>1000053716</org_study_id>
    <nct_id>NCT03118986</nct_id>
  </id_info>
  <brief_title>RCT of Olanzapine for Control of CIV in Children Receiving HSCT Conditioning</brief_title>
  <official_title>Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Chemotherapy for Hematopoietic Stem Cell Transplant Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during&#xD;
      cancer treatment according to children and their parents. Most children receiving&#xD;
      hematopoietic stem cell transplant (HSCT) conditioning experience CINV despite receiving&#xD;
      antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a&#xD;
      track record of safe use in children with psychiatric illness, does not interact with&#xD;
      chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard&#xD;
      antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving&#xD;
      chemotherapy for HSCT conditioning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of CIV control during the acute phase</measure>
    <time_frame>up to 8 days</time_frame>
    <description>Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete CINV control</measure>
    <time_frame>up to 1 month</time_frame>
    <description>CINV control - no vomiting/retching and no nausea (Pediatric Nausea Assessment Tool [PeNAT] score=1) during phase of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on toxicities</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on weight</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on Pediatric Adverse Event Rating Scale (PAERs)</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on prolactin</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on amylase</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on creatine phophotase</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of olanzapine based on triglycerides</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Based on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of olanzapine on HSCT outcomes on incidence of veno-occlusive disease</measure>
    <time_frame>From first HSCT conditioning dose until 100 days post-HSCT</time_frame>
    <description>Looking at incidence of veno-occlusive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of olanzapine on HSCT outcomes on incidence of GVHD</measure>
    <time_frame>From first HSCT conditioning dose until 100 days post-HSCT</time_frame>
    <description>Looking at incidence of GVHD between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of olanzapine on HSCT outcomes on severity of GVHD</measure>
    <time_frame>From first HSCT conditioning dose until 100 days post-HSCT</time_frame>
    <description>Comparing the incidence of the different maximal grades of GVHD between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between PeNAT and MASCC Antiemesis Tool (MAT) scores</measure>
    <time_frame>up to 1 month</time_frame>
    <description>taking maximum daily PeNAT scale score and maximum nausea experience in MAT will estimate the degree of association between PeNAT and MAT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Vomiting in Infants and/or Children</condition>
  <condition>Nausea</condition>
  <condition>Hematopoietic System--Cancer</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard antiemetics plus olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard antiemetics plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned autologous or allogeneic HSCT with a conditioning regimen that includes&#xD;
             cyclophosphamide ≥ 1 g/m^2/day (≥ 33 mg/kg/day) or highly emetogenic chemotherapy&#xD;
             (HEC)&#xD;
&#xD;
          -  Body weight of at least 12.5 kg&#xD;
&#xD;
          -  2.5 to 18 years of age. Note that the minimum body weight requirement corresponds to&#xD;
             approximately a 2.5 year old.&#xD;
&#xD;
          -  A baseline ECG within the month prior to the study drug administration without known&#xD;
             clinically significant abnormalities including pathologic prolongation of QTC.&#xD;
&#xD;
          -  Samples for all laboratory tests will be obtained within one week prior to&#xD;
             administration of the first dose of HSCT conditioning:&#xD;
&#xD;
          -  Plasma creatinine within 1.5 times the upper limit of normal for age.&#xD;
&#xD;
          -  Amylase within age-appropriate limits&#xD;
&#xD;
          -  Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless&#xD;
             attributable to Gilbert's Syndrome&#xD;
&#xD;
          -  ALT ≤ 5x upper limit of normal for age&#xD;
&#xD;
          -  A plan for scheduled, round-the-clock receipt of ondansetron, granisetron or&#xD;
             palonosetron for antiemetic prophylaxis during administration of HSCT conditioning.&#xD;
&#xD;
          -  Negative pregnancy test if female of childbearing potential&#xD;
&#xD;
          -  Patients of childbearing potential must consent to use adequate contraception (males&#xD;
             and females) or agree to practice abstinence&#xD;
&#xD;
          -  Parent or child able to speak a language in which the modified Pediatric Adverse Event&#xD;
             Rating Scale (PAERS) is available&#xD;
&#xD;
          -  Optional: Child participants in the optional assessment of nausea severity must be 4&#xD;
             to 18 years of age. Child and a parent/guardian must be English, Spanish or&#xD;
             French-speaking. The PeNAT is validated in English-speaking children 4 to 18 years old&#xD;
             with an English-speaking parent/guardian and has been translated into Spanish and&#xD;
             French. The MAT is available in English, Spanish and French.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNS malignancy, either primary CNS tumor or CNS metastases. A history of CNS leukemia,&#xD;
             in remission at study entry, is allowed.&#xD;
&#xD;
          -  Pre-existing seizure disorder; known cardiac arrhythmias; known clinically significant&#xD;
             ECG abnormalities at baseline including QTc prolongation; uncontrolled diabetes&#xD;
             mellitus; history of neuroleptic malignant syndrome; known hypersensitivity or allergy&#xD;
             to olanzapine.&#xD;
&#xD;
          -  Treatment within 14 days prior to the first day of study drug administration with&#xD;
             olanzapine or other anti-psychotic agents (e.g. risperidone, quetiapine, aripiprazole,&#xD;
             clozapine, butyrophenone) including those used to control CINV (e.g. chlorpromazine,&#xD;
             prochlorperazine, promethazine)&#xD;
&#xD;
          -  Scheduled administration (i.e. not PRN) of antiemetics other than dexamethasone and&#xD;
             ondansetron, granisetron or palonosetron is not permitted.&#xD;
&#xD;
        Scopolamine patches, aprepitant, fosaprepitant, phenothiazines (e.g. chlorpromazine,&#xD;
        prochlorperazine), acupressure or acupuncture are not permitted during the acute and&#xD;
        delayed phases. Methylprednisolone and hydrocortisone are permitted during the acute and&#xD;
        delayed phases for prevention or treatment of reaction (e.g. thymoglobulin, alemtuzumab,&#xD;
        blood products) and during delayed phase for GVHD prophylaxis. Administration of olanzapine&#xD;
        other than ordered as per study procedures is not permitted. However, other antiemetics may&#xD;
        be administered as needed (PRN) for treatment of breakthrough CINV. For patients receiving&#xD;
        busulfan, scheduled administration of benzodiazepines such as lorazepam for seizure&#xD;
        prophylaxis is permitted on the days that busulfan is given and for 24 hours after.&#xD;
&#xD;
          -  Receipt of cranial boost radiation within 14 days of the first day of HSCT&#xD;
             conditioning.&#xD;
&#xD;
          -  Planned co-administration of citalopram, amifostine, medications known to alter the&#xD;
             metabolism of olanzapine (e.g. ciprofloxacin, valproic acid)&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
&#xD;
          -  Participants in the optional assessment of nausea severity must be free of cognitive,&#xD;
             hearing or visual impairment that preclude completion of the PeNAT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Dupuis, RPh, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muhammad Ali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Dupuis, RPh, PhD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>309355</phone_ext>
    <email>lee.dupuis@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhammad Ali, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>201438</phone_ext>
    <email>muhammad.ali@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Canepa</last_name>
      <phone>415-502-2425</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy</last_name>
      <phone>816-302-6797</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University/Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaleen</last_name>
      <phone>212-305-7213</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanita</last_name>
      <phone>919-966-0017</phone>
      <email>cuffee@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Jewell</last_name>
      <email>Lori.Jewell@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta</last_name>
      <phone>843-792-1463</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Dupuis, PhD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>309355</phone_ext>
      <email>lee.dupuis@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine,</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina</last_name>
      <phone>514 345-4931</phone>
      <phone_ext>3626</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L. Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy. 2006 Sep;26(9):1221-31.</citation>
    <PMID>16945043</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Lee Dupuis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>olanzapine</keyword>
  <keyword>vomiting</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>supportive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

